(RTTNews) - Today's Daily Dose brings you news about Nektar's collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma's strategic financing; and vTv Therapeutics' initiation of a phase 1 multiple ascending dose study of HPP737.

(RTTNews) -今天的每日剂量带给你Nektar与默克合作的消息;辉瑞启动难治性多发性骨髓瘤研究;Processa Pharma的战略融资;以及vTv Therapeutics启动了HPP737的1期多剂量上升研究。

Read on...

继续阅读…

1. Nektar Teams Up With Merck

1. Nektar与默克合作

Nektar Therapeutics (NKTR) has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for a Phase 2/3 study of Bempegaldesleukin in combination with KEYTRUDA for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck.

Nektar Therapeutics (NKTR)与默克公司(Merck)达成了一项2/3期临床试验合作和供应协议，将Bempegaldesleukin联合KEYTRUDA用于头颈部转移性或不可切除复发性鳞状细胞癌的一线治疗。

Bempegaldesleukin is Nektar's drug candidate and is designed to stimulate the patient's own immune system to fight cancer. KEYTRUDA is Merck's approved blockbuster drug, which is approved for various cancers.

bempegaldesleuin是Nektar公司的候选药物，旨在刺激患者自身的免疫系统来对抗癌症。KEYTRUDA是默克公司批准的重磅药物，被批准用于治疗多种癌症。

The study is planned to start in the second half of 2021.

这项研究计划于2021年下半年开始。

Under the terms of the agreement, Nektar will conduct the Phase 2/3 study, which is expected to enroll 500 patients with metastatic or recurrent SCCHN with PD-L1 expressing tumors. The primary endpoints of the trial are overall response rate (ORR) and overall survival (OS); progression-free survival (PFS) is a secondary endpoint.

根据协议条款，Nektar将开展这项2/3期研究，预计将招募500名PD-L1表达的转移性或复发性SCCHN患者。试验的主要终点是总应答率(ORR)和总生存期(OS);无进展生存期(PFS)是次要终点。

The company also inked a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin. As part of the deal, Nektar is all set to receive up to $150 million to support the study and manage clinical trial operations.

该公司还与SFJ Pharmaceuticals签署了融资和联合开发合作协议，以支持bempegaldesleuin的开发。作为交易的一部分，Nektar将获得1.5亿美元，用于支持研究和管理临床试验操作。

NKTR closed Wednesday's trading at $25.46, up 13.36%.

NKTR周三收于25.46美元，上涨13.36%。

2. Pfizer Initiates Multiple Myeloma Trial

2. 辉瑞启动多发性骨髓瘤试验

Pfizer Inc. (PFE) has initiated a pivotal phase II study of investigational drug Elranatamab in patients with relapsed/refractory multiple myeloma.

辉瑞公司(PFE)启动了一项关键的实验性药物埃瑞那他单抗(Elranatamab) II期临床研究，用于复发/难治性多发性骨髓瘤患者。

The study, dubbed MagnetisMM-3, is designed to enroll approximately 150 people with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody.

这项研究被命名为magnesmm -3，旨在招募大约150名对至少一种蛋白酶体抑制剂、一种免疫调节药物和一种抗cd38单克隆抗体难治性多发性骨髓瘤患者。

The study's estimated primary completion date is June 2022.

这项研究预计将于2022年6月初步完成。

In other news, Pfizer and BioNTech SE (BNTX) announced an agreement with the European Commission to supply an additional 200 million doses of their COVID-19 vaccine COMIRNATY, also known as BNT162b2. The European Commission has the option to request supply of an additional 100 million doses.

其他方面，辉瑞和生物科技公司(BNTX)宣布与欧盟委员会达成协议，将额外供应2亿剂COVID-19疫苗，也称为BNT162b2。欧洲委员会可以选择要求额外供应1亿剂。

Albert Bourla, Chairman and Chief Executive Officer of Pfizer said, "With this new agreement with the European Commission, we now expect to deliver enough doses to vaccinate at least 250 million Europeans before the end of the year."

辉瑞公司董事长兼首席执行官Albert Bourla说:“有了与欧盟委员会达成的这项新协议，我们现在预计在今年年底之前，将为至少2.5亿欧洲人提供足够的疫苗。”

PFE closed Wednesday's trading at $34.89, up 0.58%.

PFE周三收于34.89美元，上涨0.58%。

3. Processa Strengthens Balance Sheet

3.Processa加强资产负债表

Shares of Processa Pharmaceuticals Inc. (PCSA) jumped more than 30%, following a $10.2 million strategic financing.

Processa制药公司(Processa Pharmaceuticals Inc.)在获得1,020万美元战略融资后，股价上涨超过30%。

As part of the financing, the company sold 1.32 million shares through private investment in public equity (PIPE) financing at a price of $7.75 per share.

作为融资的一部分，该公司以每股7.75美元的价格，通过私募股权融资(PIPE)出售了132万股股票。

The financing attracted both institutional and accredited investors, noted the company. The closing of the private placement is expected to occur on or about February 23, 2021.

该公司指出，此次融资既吸引了机构投资者，也吸引了认可投资者。此次私募交易预计将于2021年2月23日结束。

The company's lead product candidate is oral PCS499, proposed for the treatment of Necrobiosis Lipoidica, under phase IIb trial. Another compound PCS6422 is under a phase Ib study in combination with capecitabine as first-line therapy for metastatic colorectal cancer. The company expects results from the interim analyses in the phase 1B PCS6422 study and the Phase 2B PCS499 study in the second half of this year.

该公司的主导候选产品是口服PCS499，目前正在进行IIb期临床试验，拟用于治疗脂质坏死。另一种化合物PCS6422与卡培他滨联合作为转移性结直肠癌的一线治疗方案正在进行Ib期研究。该公司预计今年下半年将获得1B期PCS6422研究和2B期PCS499研究的中期分析结果。

PCSA closed Wednesday's trading at $10.76, up 33.17%.

PCSA周三收于10.76美元，上涨33.17%。

4. vTv Therapeutics On Track

4. vTv疗法步入正轨

vTv Therapeutics Inc. (VTVT) has initiated a phase 1 multiple ascending dose study of HPP737 in healthy adult volunteers.

vTv Therapeutics Inc. (VTVT)在健康成人志愿者中启动了HPP737的1期多上升剂量研究。

HPP737 is a novel, potent, orally administered PDE4 inhibitor discovered by vTv Therapeutics. PDE4 has been demonstrated to be a validated therapeutic target for the treatment of a variety of disorders including psoriasis.

HPP737是vTv Therapeutics公司发现的一种新型、有效的口服PDE4抑制剂。PDE4已被证明是一种有效的治疗靶点，可治疗包括银屑病在内的多种疾病。

The phase I multiple ascending dose study is expected to be completed in Q2 2021.

一期多次上升剂量研究预计将于2021年第二季度完成。

Meanwhile, the company's strategic partner, Newsoara Biopharma, has initiated a proof of concept phase II study of HPP737 in chronic obstructive pulmonary disease (COPD) in China. Newsoara is also initiating phase 2 studies with HPP737 in psoriasis and atopic dermatitis this year.

与此同时，该公司的战略合作伙伴Newsoara Biopharma在中国启动了HPP737治疗慢性阻塞性肺疾病(COPD)的概念II期研究。Newsoara也在今年启动了HPP737治疗银屑病和特应性皮炎的二期研究。

VTVT closed Wednesday's trading at $2.84, up 6.77%.

VTVT周三收于2.84美元，上涨6.77%。

5. Stocks That Gained/Lost The Most In A Day

5. 单日涨跌最大的股票

Predictive Oncology Inc. (POAI) closed Wednesday's (Feb.17, 2021) trading at $2.20, up 34.15%.

预测肿瘤公司(POAI)周三(2021年2月17日)收于2.20美元，上涨34.15%。

Shineco Inc. (TYHT) closed at $5.68, up 32.09%.

Shineco Inc.收于5.68美元，上涨32.09%。

Check-Cap Ltd. (CHEK) closed at $2.33, up 29.44%.

Check-Cap有限公司(CHEK)收于2.33美元，上涨29.44%。

Interpace Biosciences, Inc. (IDXG) closed at $4.44, down 23.97%.

Interpace Biosciences公司(IDXG)收于4.44美元，下跌23.97%。

AIkido Pharma Inc. (AIKI) closed at $1.68, down 21.13%.

合气道制药公司(AIKI)收于1.68美元，下跌21.13%。